We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Test Predicts Response to Weight Loss Medications

By LabMedica International staff writers
Posted on 22 Sep 2025

Obesity is a chronic and complex disease affecting more than 650 million adults worldwide, driven by a mix of genetic, environmental, and behavioral factors. More...

This complexity explains why people respond so differently to weight-loss interventions, yet treatment decisions often rely on simple measures such as body mass index. Researchers have now demonstrated that biological signals of satiation can be used to predict which medications will be most effective, offering a pathway to more personalized care.

Researchers at the Mayo Clinic (Rochester, MN, USA) have developed a genetic test that estimates an individual’s calories to satiation (CTS), or the amount of food it takes for someone to feel full. The test uses a metric called the Calories to Satiation Genetic Risk Score (CTS-GRS), created by combining variants in 10 genes linked to food intake. Calculated from a blood or saliva sample, this score provides a personalized estimate of satiation thresholds that can be used to guide treatment.

In a study of nearly 800 adults with obesity, participants ate an all-you-can-eat meal until they felt “uncomfortably full,” revealing wide variation in intake, ranging from 140 to more than 2,000 calories. Traditional factors such as body size, fat percentage, hormones, and age only explained a small part of this variation. Applying the CTS-GRS in clinical trials, researchers found that people with a high satiation threshold lost more weight on phentermine-topiramate, while those with a low threshold responded better to liraglutide.

The findings, published in Cell Metabolism, show that one genetic test can predict which patients are most likely to succeed on two different medications, enabling more cost-effective care and better health outcomes. The research team is expanding the test to include responses to semaglutide and incorporating microbiome and metabolome data. They are also working on predictive models for common side effects such as nausea, aiming to further refine and personalize obesity treatments.

“Patients deserve treatments that reflect their biology, not just their body size. This test helps us deliver the right medication to the right person from the start,” said Dr. Andres Acosta, gastroenterologist at Mayo Clinic and senior author of the study. "With one genetic test, we can predict who is most likely to succeed on two different medications. That means more cost-effective care and better outcomes for patients."

Related Links:
Mayo Clinic


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.